JNK
Drug
Celgene Corporation
Total Payments
$16,896
Transactions
2
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $13,056 | 1 | 0 |
| 2018 | $3,840 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $16,896 | 2 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Prospective Validation of Cough, Dyspnea, and Quality of Life Questionnaires in Patients With Idiopathic Pulmonary Fibrosis (JK-IPF-PI-0004) | Celgene Corporation | $13,056 | 0 |
| JK-IPF-PI-0004 - Prospective Validation of Cough, Dyspnea, and Quality of Life Questionnaires in Patients With Idiopathic Pulmonary Fibrosis | Celgene Corporation | $3,840 | 0 |
Top Doctors Receiving Payments for JNK
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | San Francisco, CA | $16,896 | 2 |
Ad
Manufacturing Companies
- Celgene Corporation $16,896
Product Information
- Type Drug
- Total Payments $16,896
- Total Doctors 0
- Transactions 2
About JNK
JNK is a drug associated with $16,896 in payments to 0 healthcare providers, recorded across 2 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.
Payment data is available from 2018 to 2019. In 2019, $13,056 was paid across 1 transactions to 0 doctors.
The most common payment nature for JNK is "Unspecified" ($16,896, 100.0% of total).
JNK is associated with 2 research studies, including "Prospective Validation of Cough, Dyspnea, and Quality of Life Questionnaires in Patients With Idiopathic Pulmonary Fibrosis (JK-IPF-PI-0004)" ($13,056).